• eTheRNA
  • Follow our progress in developing products that have the potential to transform the future of cancer treatment

eTheRNA immunotherapies to present at Sachs Biotech in Europe Forum

Niel (Belgium), 21 September 2017 — eTheRNA immunotherapies, a clinical-stage company developing mRNA-based cancer immunotherapies from its unique TriMix platform, announces that its CEO Dirk Reyn is to present an overview of the company, its novel technologies and development pipeline at the Sachs 17th Biotech in Europe Forum for Global Partnering and Investment.

The presentation will take place on 27 September at 12:15pm in Presentation Track C, which takes place at the Congress Center, Basel, Switzerland.

The Sachs Biotech in Europe Forum for Global Partnering and Investment is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry. The forum brings together a cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. More than 600 delegates are expected to attend.